Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).

Sant P Chawla,Walter Andree Tellez,Hripsime Chomoyan,Chrysler Valencia,Amir Ahari, Nadezhda Omelchenko, Stefan Makrievski,Don A Brigham,Victoria Chua-Alcala,Doris Quon,Ania Moradkhani,Erlinda M Gordon

Frontiers in oncology（2023）

引用 0|浏览6

暂无评分

摘要

Taken together these data suggest that the TNT regimen is effective and safe for advanced previously treated sarcomas, and is worth being further studied in a randomized phase 3 trial as first- or second- line treatment for patients with advanced sarcomas.

查看译文

关键词

talimogene laherparepvec, nivolumab, trabectedin, sarcoma, immunotherapy, alkylating agents

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要